Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Uhlik

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Hematology & Oncology|April 30, 2013
Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibitionBeverly L Falcon, Belinda O'Clair, Don McClure, et al.
Molecular Cancer Therapeutics|December 16, 2014
Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic modelsSheng-Bin Peng, Xiaoyi Zhang, Donald Paul, et al.
Molecular Cancer Research : MCR|April 21, 2012
Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypesMelinda D Willard, Mary E Lajiness, Isabella H Wulur, et al.
Frontiers in Oncology|June 13, 2022
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor AntibodiesAnissa S H Chan, Takashi O Kangas, Xiaohong Qiu, et al.
Molecular Cancer Therapeutics|February 22, 2019
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor InhibitionAnthony S Fischl, Xiaoen Wang, Beverly L Falcon, et al.
Molecular and Cellular Biology|October 4, 2005
Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryoAmy N Abell, Jaime A Rivera-Perez, Bruce D Cuevas, et al.
Investigational New Drugs|March 2, 2011
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft modelTimothy P Burkholder, Joshua R Clayton, Mark E Rempala, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy VolunteersNandita Bose, Nadine R Ottoson, Xiaohong Qiu, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Cancer Research|May 20, 2016
Stromal-Based Signatures for the Classification of Gastric CancerMark T Uhlik, Jiangang Liu, Beverly L Falcon, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Hematology & Oncology|April 30, 2013
Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibitionBeverly L Falcon, Belinda O'Clair, Don McClure, et al.
Molecular Cancer Therapeutics|December 16, 2014
Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic modelsSheng-Bin Peng, Xiaoyi Zhang, Donald Paul, et al.
Molecular Cancer Research : MCR|April 21, 2012
Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypesMelinda D Willard, Mary E Lajiness, Isabella H Wulur, et al.
Frontiers in Oncology|June 13, 2022
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor AntibodiesAnissa S H Chan, Takashi O Kangas, Xiaohong Qiu, et al.
Molecular Cancer Therapeutics|February 22, 2019
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor InhibitionAnthony S Fischl, Xiaoen Wang, Beverly L Falcon, et al.
Molecular and Cellular Biology|October 4, 2005
Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryoAmy N Abell, Jaime A Rivera-Perez, Bruce D Cuevas, et al.
Investigational New Drugs|March 2, 2011
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft modelTimothy P Burkholder, Joshua R Clayton, Mark E Rempala, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy VolunteersNandita Bose, Nadine R Ottoson, Xiaohong Qiu, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Cancer Research|May 20, 2016
Stromal-Based Signatures for the Classification of Gastric CancerMark T Uhlik, Jiangang Liu, Beverly L Falcon, et al.
Pageof 2